Bristol Myers Squibb announces a 10-year strategy called ASPIRE, aimed at advancing access to its innovative treatments and helping patients in low- and middle-income countries gain access to life-saving medicines.

This strategy supports the pharmaceutical company's commitment to reach more than 200,000 patients in low- and middle-income countries with its innovative treatments.000 patients in low- and middle-income countries by 2033 with its innovative treatments.

In particular, Bristol Myers is entering into a strategic collaboration with the Access to Medicines in Oncology Coalition (ATOM) to expand access to its Opdivo immuno-oncology therapy in selected countries.

Copyright (c) 2024 CercleFinance.com. All rights reserved.